Book Your Vaccination Appointment

Individuals 6 months or older are eligible for their first dose.

Eligibility between vaccines is based on age:

6 months to under 5 years: There is a Pfizer and Moderna pediatric product available for this group. Both products are equally recommended, unless the individual is immunocompromised, in which case Moderna is recommended. Pfizer requires 3 doses to complete the primary series.

5 years to 11 years: Pfizer is the preferred vaccine for this age group, however, a Moderna product is also available.

12 years to 29 years: Pfizer is the preferred vaccine for this age group, however, a Moderna product is also available.

30+ years: There is no preference between Pfizer or Moderna vaccines for this group.

It is recommended that individuals complete their primary series using the same product if possible.

56 days (8 weeks) is the recommended interval between dose #1 and #2 for all ages. For infant Pfizer, (3 dose primary series), 56 days is also the minimum and recommended interval between dose #2 and dose #3.

Immunocompromised individuals: Moderately to severely immunocompromised individuals are eligible for a three-dose primary series. Their primary series is considered complete after the 3^rd dose has been administered.

The following groups are eligible for an extended primary series (3^rd Primary Series Dose):

• Individuals receiving dialysis (hemodialysis or peritoneal dialysis)
• Individuals receiving active treatment1 (e.g., chemotherapy, targeted therapies, immunotherapy) for solid tumour or hematologic malignancies Recipients of solid-organ transplant and taking immunosuppressive therapy
• Recipients of chimeric antigen receptor (CAR)-T-cell therapy or hematopoietic stem cell transplant (within 2 years of transplantation or taking immunosuppression therapy)
• Individuals with moderate to severe primary immunodeciency (e.g., DiGeorge syndrome, Wiskott-Aldrich syndrome)
• Individuals with stage 3 or advanced untreated HIV infection and those with acquired immunodeciency syndrome
• Individuals receiving active treatment with the following categories of immunosuppressive therapies: anti-B cell therapies2 (monoclonal antibodies targeting CD19, CD20 and CD22), high-dose systemic corticosteroids (refer to the Canadian Immunization Guide for suggested definition of high dose steroids), alkylating agents, antimetabolites, or tumor-necrosis factor (TNF) inhibitors and other biologic agents that are significantly immunosuppressive

6 months - 4 years: no booster dose is approved or available.

5 years +: 6 months (168 days) after last dose or confirmed SARS-CoV-2 infection.
It is recommended you receive only 1 booster after September 1^st 2022, unless you meet the requirements for a Spring Booster.

Spring Booster: At risk populations are eligible for an additional booster if they meet criteria:

• Individuals aged 65 years and older;
• Residents of long-term care homes, retirement homes, Elder Care Lodges, and other congregate living settings for seniors;
• Individuals aged 18 years and older living in a congregate care setting for people with complex medical care needs;
• Pregnant individuals;
• Individuals aged 18 years and older who are moderately to severely immunocompromised; and
• Individuals aged 55 years and older who identify as First Nations, Inuit, or Métis and their non-Indigenous household members aged 55 years and older.